Stockholm 1 October 2019
Open Letter to Immunicum AB (publ) Shareholders
Proposal to the Nomination Committee for Immunicum AB (publ) and the 2020 Annual General Meeting
Compensation to the Board of Directors
Creopretium including related parties note that a majority of the board do not hold shares or hold a negligible number of shares in Immunicum AB (publ) in relation to compensation.
Table 1. Immunicum Board of Directorsʼ ownership and compensation
Number of shares
Compensation 2018, kSEK
Total compensation since appointment, kSEK
Value kSEK/total comp since appointment, (x)
Michael Oredsson, Chairman
Kerstin Valinder Strinnholm
Source: Immunicum AB (publ)
Creopretiumʼs rational behind the proposal:
Creopretiumʼs assessment is that this proposal to the annual general meeting 2020 is in the interest of all shareholders.
1 Under normal circumstances purchased shares shall not be divested before directorship has ended.
Creopretium AB ("Creopretium") is a local operating partner to investors active in the Nordics. Creopretium offers advisory and co-investments where exceptional value can be unlocked through active ownership. Creopretium is a privated limited liability company under the laws of Sweden and registered with Swedish Companies Registration Office. Corporate registration number 556882–0111. The registered office of the board is in Stockholm, Sweden. For more information about Creopretium, please visit https://creopretium.se